mDETECT is a DNA-methylation-based liquid biopsy company that has developed a highly specific and sensitive blood test for the detection and management of metastatic breast cancer. The test can rapidly and accurately determine the tumor burden in patients to assess therapy response. Blood tests for prostate cancer and uveal melanoma are also part of the portfolio.